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Why do we need to eradicate pathogens in respiratory 
tract infections? 
Javier Garau@) 
Evidence from studies in otitis media, acute bacterial sinusitis and acute exacerbations of chronic bronchitis indicate 
that clinical efficacy is dependent on bacterial eradication. Failure to eradicate bacterial pathogens increases the 
potential for clinical failure, incurring further costs, and may also select and maintain bacteria that are resistant to a 
wide range of antimicrobials. Bacteriologically confirmed clinical failures have been reported in pneumococcal 
pneumonia with both macrolides and older fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). These 
failures were due to the involvement of resistant pathogens (macrolides) or suboptimal pharmacokineticsipharmaco- 
dynamics (PK/PD) (q uinolones). However, persistent positive blood cultures have not been reported during therapy 
with adequate doses of benzylpenicillins or aminopenicillins. Treatment failure, driven by the failure to eradicate 
pathogens, leads to both economic and environmental costs, hospitalization being the major cost driver. Failure to 
achieve bacterial eradication may also lead to the development and spread of resistance. Different types of anti- 
microbials appear to be driving resistance to different extents, and this may be due to suboptimal PWPD. In conclusion, 
factors to consider when prescribing include an accurate diagnosis, knowledge of local epidemiology, the role of 
PK/PD principles in antimicrobial choice, clinical outcomes in relation to bacteriologic efficacy, and resistance and 
its bacteriologic and clinical impact. The vicious cycle of infection, inappropriate therapy, bacteriologic failure, 
selection/spread of resistance and further infection needs to be broken by the use of appropriate treatments to 
achieve bacterial eradication. 
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INTRODUCTION 
Suboptimal prescribing continues to be a widespread 
problem in the treatment of community-acquired 
respiratory tract infection (RTI).i Suboptimal prescribing 
not only increases the risk of clinical failure and the 
attendant costs of further treatment, but is also an 
avoidable risk factor for the development and spread of 
bacterial resistance.2 Until recently, antimicrobial choice 
was based solely on clinical data obtained from trials 
often powered only to show equivalence between agents 
(see J.-H. Song, this issue). However, advances in our 
understanding of pharmacodynamics (PD) and pharma- 
cokinetics (PK) now enable us to predict antimicrobial 
bacteriologic efficacy (see M. R. Jacobs, this issue). Anti- 
microbials target bacterial infection, and they should be 
judged on their ability to eradicate the infection, rather 
than on what is effectively a secondary endpoint, clinical 
cure. 
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BACTERIAL ERADICATION MAXIMIZES 
CLINICAL SUCCESS 
Bacterial eradication is accepted as a requirement for 
clinical success in a number of infections, such as menin- 
gitis and osteomyelitis. However, its necessity in RTIs 
has been debated.2 Confirmed bacteriologic and clinical 
failure of antimicrobial therapy is difficult to detect in 
RTIs, due to the high spontaneous resolution rate of 
many of these infections, and the difficulty in obtaining 
microbiological samples.2 As a result, otitis media has 
been used as a model to investigate in vivo antimicrobial 
bacteriologic activity in humans. This infection involves 
the same major causative pathogens as other community- 
acquired RTIs, and has the advantage that samples of 
middle ear fluid can be taken before and after anti- 
microbial therapy (double tympanocentesis) to directly 
assess antibacterial efficacy (see R. Dagan, this issue). 
The association of bacterial eradication with improved 
clinical response in otitis media was first shown directly 
by Dagan et a1.3 In their double-tympanocentesis study 
of 123 children with acute otitis media treated with 
various antimicrobials, clinical failure was significantly 
associated with failure to eradicate bacteria from the 
middle ear after 3-4 days (p<O.OOl) (Figure 1). Further- 
more, clinical scores for both moderate and severe 
disease improved significantly faster in children from 
whom bacteria were eradicated than in those who were 
still culture positive after 3-4 days3 
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Figure 1. Clinical outcomes of 57 children with bacteriologic 
failure versus 66 children with bacterial eradication 3-4 days 
after starting antimicrobial treatment for acute otitis media. 
Adapted with permission from Dagan et al.3 
Studies of antimicrobial therapy of acute exacer- 
bations of chronic bronchitis have also indicated that 
maximizing bacteriologic efficacy is associated with im- 
proved clinical cure. For example, in an open randomized 
trial of 142 patients with acute exacerbations of chronic 
bronchitis, the bacteriologic efficacy of azithromycin 
was 67%, and clinical cure or improvement was also 
67% .4 In comparison, amoxicillin-clavulanate achieved 
bacteriologic success in 99% of patients, and this was 
translated into a clinical success rate of 97%.4 These 
results are supported by a retrospective review of the 
literature for comparative studies of antimicrobial 
therapy of acute exacerbations of chronic bronchitis that 
had bacteriologic data.5 Twelve studies, using 16 anti- 
microbials in 26 treatment regimens, were identified, and 
there was a strong correlation (r = 0.91) between clinical 
failure and the corresponding eradication rate (Figure 2). 
Studies such as those outlined above indicate that maxi- 
mizing the potential for bacterial eradication will also 
maximize clinical success. 
IMPACT OF BACTERIAL RESISTANCE ON 
PATIENT OUTCOME 
In many regions of the world, the prevalence of bacterial 
pathogens with decreased susceptibility to common 
antimicrobials is increasing, and threatens to undermine 
the efficacy of some agents6 The impact of resistance 
on bacterial eradication has been clearly shown in otitis 
media.7 In a prospective, open, randomized comparison 
of oral azithromycin and oral cefaclor in children with 
acute otitis media, all the Streptococcus pneumoniae 
isolates eradicated after azithromycin therapy had 
azithromycin MICs 50.06 mg/L. In contrast, all of the six 
patients with bacteriologic failure after azithromycin 
therapy had S. pneumoniae isolates with azithromycin 
MICs ~32 mg/L.7 Similarly, 79% of S. pneumoniae iso- 
lates with a cefaclor MIC below 0.5 mg/L were eradi- 
cated, compared with only 32% of those with an MIC of 
0.5 mg/L or above.7 A clinical breakpoint of 0.5 mg/L for 
cefaclor corresponds to that predicted using PK/PD 
principles (see M. R. Jacobs and R. Dagan, this issue). 
In RTIs, determining the impact of in vitro ‘resistance’ 
on bacterial and clinical outcome is very difficult. It is 
only relatively recently that bacteriologically defined 
failures due to resistant organisms have been described 
in community-acquired pneumonia. 
Penicillin resistance 
Despite the documented high prevalence of penicillin 
resistance worldwide,6 there are surprisingly few reports 
showing that this by itself is an indicator of poorer 
clinical outcome. However, at least three recent papers 
suggest that the presence of penicillin-resistant pneumo- 
cocci causing invasive disease is an independent pre- 
dictor of poor clinical outcome.8-10 Unfortunately, all of 
these reports have confounding factors that cloud any 
interpretations regarding therapy failure. Turett et al 
did find that S. pneumoniae strains with penicillin MICs 
of more than 2 mg/L were independently associated 
with mortality.8 However, no adjustment was made for 
severity of illness, and 50% of the patients in the study 
were HIV-positive with impaired immune status (mean 
CD4+=122 cells/mm3).8 Feikin et al found that patients 
infected with S. pneumoniae strains with penicillin MICs 
of over 4 mg/L had an increased risk of death, once 
deaths after 4 days had been adjusted for.9 Again, this 
study was not adjusted for severity of illness, and as 
there was no information given on antimicrobial 
treatment, it is impossible to say whether failure was due 
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Figure 2. Positive correlation between bacteriologic eradication 
failure rates in acute exacerbations of chronic bronchitis and 
associated clinical failure rates from the published literature, 
1990-97. Redrawn with permission from PechPre.s 
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to insufficient therapy.9 Metlay et al found a significant 
association between penicillin-non-susceptible pneumo- 
coccal infection and in-hospital death (relative risk 2.1, 
95% CI 1.0-4.3). However, this association disappeared 
after adjustment for severity of illness (relative risk 
1.7, 95% CI 0.8-3.4), indicating the importance of this 
parameter.lO None of the above studies provides full 
information regarding the antimicrobial regimens used, 
and it is impossible to determine whether failure of 
penicillin therapy due to penicillin resistance or another 
factor, such as disease severity, was responsible for the 
poor outcome. In fact, there is still no documented case 
of bacteriologic failure of penicillin when given at an 
appropriate dose against a penicillin-resistant strain in 
bacteremic pneumococcal pneumonia. 
Several recent studies indicate that in vitro penicillin 
resistance may not actually compromise clinical outcome 
in invasive pneumococcal disease, excluding meningitis. 
For example, a mouse model of peritoneal virulence 
indicated that penicillin-resistant pneumococci may 
actually be less virulent than susceptible strainsrl In this 
model, 32 clinical isolates of S. pneumoniae were virulent 
and susceptible to penicillin (irrespective of their sero- 
type), whereas 41 isolates with diminished susceptibility 
or resistance to penicillin were avirulent; the remain- 
ing 49 strains were both susceptible to penicillin and 
avirulent, irrespective of the serotype.ll There are also 
clinical data indicating that in vitro penicillin resistance 
has yet to have an impact on clinical outcomes.12-14 
In a study of patients with invasive pneumonia due to 
S. pneumoniae with a cefotaxime MIC of 0.25 mg/L or 
more, and matched subjects with more susceptible 
S. pneumoniae strains, antimicrobial resistance did not 
contribute significantly to mortality or the requirement 
for intensive care.12 In contrast, severity of disease at 
presentation was found to have a strong influence on 
outcomes in pneumococcal pneumonia.12 In a study of 
invasive infection in pediatric patients, no difference was 
found in clinical presentation, morbidity or mortality 
between patients infected with either susceptible or 
non-susceptible pneumococci.13 Similarly, a study of 
465 adults treated for pneumococcal pneumonia with 
p-lactam antimicrobials reported no difference in 
mortality between patients infected with penicillin- 
susceptible strains (18%) and those infected with 
intermediate or resistant strains (14%).14 In this latter 
study, the MIC of penicillin for the penicillin-resistant 
isolates was 2 mg/L or higher. 
The lack of evidence for any impact of in vitro 
penicillin resistance on clinical outcomes with penicillin 
therapy in pneumococcal pneumonia may be explained 
by the flexibility of dosing available for this class of 
agents. For penicillins, in vitro resistance can be over- 
come by increasing the dose, and intravenous doses 
of benzylpenicillin up to 24 million units over 24 h or 
4 million units every 6 h can be safely administered.15 
This is not the case for macrolides and fluoroquino- 
lones-the therapeutic windows of these classes are 
smaller, and doses are consequently limited by safety 
concerns. 
Macrolide resistance 
The first cases of in vivo failure of macrolide treatment 
for pneumococcal pneumonia were reported in 1992,i6 
but sporadic reports of bacteriologic and clinical failure, 
amounting to 22 cases in total, have also appeared more 
recently (Table 1) .17-21 Failures have occurred not only 
with erythromycin, but also with the newer agents 
azithromycin, clarithromycin, and josamycin. Several 
of the S. pneumoniae strains isolated in these studies 
had erythromycin MICs as low as 4 mg/L.18 Macrolide 
failure in these cases of pneumococcal pneumonia could 
represent a true failure of therapy, or could have been 
due to poor drug absorption or poor patient compliance. 
In order to determine the cause of macrolide failure 
in pneumococcal pneumonia, Lonks et al undertook a 
case-control study of 1071 patients with pneumococcal 
Table 1. Reports of macrolide failures in pneumococcal pneumonia due to macrolide resistance17-21 
Author Year 
Number of Blood Days of Macrolide 
cases cultures therapy (no. of patients) 
Phenotype or 
susceptibility at failure 
(no. of patients) 
Garau et al 2000 12 
Kelly et al 2000 4 
Fogarty et al 2000 3 
Waterer 2000 1 
Deligne et al 2001 2 
2-8 (3)” 
3-5 
3-5 
3-5 
- 
ERY (3) 
CLARI (3) 
AZI (3) 
JOSA (2) 
AZI 
AZI 
AZI 
CLARI 
MLSB (IO) 
M (2) 
ERY, 8-16 mg/L, 
susceptible to CLIN 
AZI, 8 mg/L (2) 
>I28 mg/L (I) 
ERY, 16 mg/L 
ERY, 32-256 mg/L, 
resistant to CLIN 
Total 22 All + 2-8 All macrolides 
ERY, erythromycin; CLARI, clarithromycin; AZI, azithromycin; JOSA, josamycin; Cl-IN, clindamycin, aMean. 
M and MLSB phenotypes 
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bacteremia in three hospitals in the USA and one 
hospital in Spain.22 If lack of compliance or poor absorp- 
tion were the reasons for clinical failure, macrolide use 
would be expected to be equally represented in cases 
and in controls. Of 86 bacteremia cases from whom 
an erythromycin-resistant S. pneumoniae isolate was 
obtained, 19 (22%) were taking a macrolide when 
blood cultures were drawn, compared with none of 
the 141 controls from whom erythromycin-susceptible 
S. pneumoniae strains were isolated (p<O.OOOl). This 
study also indicates that low-level pneumococcal 
macrolide resistance, conferred by the mef genotype, 
is sufficient to result in macrolide failure. Although 
the errrz gene, which codes for ribosomal methylase, 
was found in 10 of 11 isolates from patients in Spain 
with erythromycin-resistant S. pneumoniae strains, six 
of eight isolates from patients in the USA with 
erythromycin-resistant S. pneumoniae strains had the 
mef gene or the M phenotype, consistent with macrolide 
efflux. The MICs of the erythromycin-resistant strains 
ranged from as low as 4 mg/L to more than 128 mg/L for 
strains with the mef and erm genes, respectively.22 This 
case-control study provides strong evidence that in vitro 
macrolide resistance is currently resulting in clinical 
failures with macrolide therapy in the treatment of 
pneumococcal pneumonia.22 
Recently, the emergence of in vivo macrolide 
resistance while on therapy has been documented in a 
previously healthy man who received empirical therapy 
with intravenous azithromycin for pneumococcal pneu- 
monia.23 His condition improved rapidly, but then 
suddenly deteriorated on the fourth day of treatment, 
and, despite receiving ceftriaxone and vancomycin, he 
died. On admission, S. pneumoniae was cultured from 
sputum (blood cultures were negative), and proved to 
be fully susceptible to penicillin, clindamycin, and 
macrolides. When the patient’s condition deteriorated, 
the isolates of S. pneumoniae cultured from broncho- 
alveolar lavage and pleural fluid were genotypically 
identical to the initial sputum isolate, and were still 
susceptible to penicillin and clindamycin, but had 
developed resistance to azithromycin, erythromycin, 
and quinupristin-dalfopristin, with MICs in the range 
2-4 mg/L. Molecular genetic analysis showed that the 
increase in macrolide MIC was not due to erm or mef, 
but to a mutation in the gene for ribosomal protein 
L22.23,24 
Fhoroquinolone resistance 
Older fluoroquinolones, particularly ofloxacin and 
ciprofloxacin, have been associated with treatment 
failure in pneumococcal pneumonia.25-27 These failures 
are not due to acquired resistance, but to the poor 
activity of these agents against Gram-positive patho- 
gens. 25-27 The introduction of newer agents in this class 
with increased Gram-positive activity has led to the 
expanded use of fluoroquinolones in pneumococcal 
infection. However, reports are emerging of bacterio- 
logically confirmed failures, particularly with levofloxacin. 
Levofloxacin is the least active of the new fluoroquino- 
lones against S. pneumoniae, with MICs clustered near 
the breakpoint-the MI& of levofloxacin is almost 
uniformly 1 mg/L worldwide, and the breakpoint is 
2 mg/L.6 Among five cases of failure reported since 1999, 
all were infected with strains of S. pneumoniae that were 
already resistant to levofloxacin, with MICs ranging 
from >4 mg/L to >32 mg/L.28m30 Three of these patients 
had been exposed to fluoroquinolones in the recent 
past. 28,29 Even though the prevalence of fluoroquinolone 
resistance is currently very 10w,~ it is already having an 
impact on clinical outcomes. As the use of these agents 
increases, so will the prevalence of resistance, and 
further reports of clinical failures can be anticipated. 
More worrying is the emerging evidence that 
levofloxacin is selecting for resistance during therapy.31 
Pneumococcal resistance to fluoroquinolones develops 
in a stepwise manner, as successive mutations emerge, 
producing incremental increases in the MIC.31 A recent 
report described four cases of treatment failure with 
levofloxacin in pneumococcal pneumonia, two of which 
had fluoroquinolone resistance emerge during levo- 
floxacin therapy. 31 In one patient, levofloxacin resistance 
developed during treatment; in another, an intermediate 
strain progressed to become fully resistant, and new 
resistance mutations were identified (Table 2). As resist- 
Table 2. Microbiological characteristics of 5. pneumoniae isolated before, during or after therapy with levofloxacin from four 
patients with community-acquired pneumonia. Data from Davidson et a131 
MIC (mglL) Amino acid substitution 
Patient Source and time Serotype Levofloxacin Moxifloxacin Gatifloxacin ParC GyrA 
1 Sputum before 
Sputum after 
2 Sputum before 
Sputum during 
3 Blood before 
Pleural fluid 
during 
4 Sputum during 
23F 1 6) 0.12 (S) 0.25 (S) 
23F 8 CR) 1 (9 2 0) S79F S81F 
6A 4 (0 0.25 (S) 0.5 (5) S79F 
6A 16 CR) 4 (W 4 (R) S79F S8lF 
14 16 W 4 09 2 0) S79F S81Y 
14 16 (RI 4 (R) 2 0) S79F and S81Y 
D83Y 
ND 16 03 4 (RI 8 (R) S79Y E85K 
5, susceptible; I, intermediate; R, resistant. 
-, no mutation found; ND, not determined. 
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ante to levofloxacin developed, the MICs of the other 
new quinolones, moxifloxacin and gatifloxacin, also 
increased. The two remaining patients had a history 
of previous levofloxacin and/or ciprofloxacin usage, 
and S. pneumoniae strains with a levofloxacin MIC of 
16 mg/L were cultured before and during levofloxacin 
treatment.31 The emergence of resistance on therapy 
indicates that therapy is suboptimal, promoting the 
selection of resistance, rather than eradicating the 
pathogen. 
BACTERIOLOGIC FAILURE PROMOTES 
ANTIMICROBIAL RESISTANCE 
Suboptimal therapy that fails to achieve bacterial 
eradication not only compromises clinical success, but 
also increases the potential for the development and 
spread of bacterial resistance. The impact of suboptimal 
therapy on oropharyngeal carriage of S. pneumoniae 
was assessed in an observational study by Guillemot et 
al in healthy 3-6-year-old children in 20 randomly 
selected schools.32 Among those children who had not 
used a l3-lactam, 77% of S. pneumoniae nasopharyngeal 
isolates had a penicillin MIC ~0.1 mg/L. Among children 
who had received at least one p-lactam course in the 
previous 30 days, all the S. pneumoniae isolates from 
those who had received a daily dose below the median 
for the cohort had penicillin MICs >O.l mg/L. In 
contrast, all the S. pneumoniae isolates from the children 
who had received a daily dose above the median had 
penicillin MICs co.1 mg/L (p=O.O03). The three main 
factors that were found to predict oropharyngeal carriage 
Table 3. Risk factors for increased nasopharyngeal carriage of 
penicillin-resistant 5. pneumoniae in young school children. 
Data from Guillemot et al32 
Risk factor 
Oral p-lactam use in 
the past 30 days 
Dose lower than clinically 
recommended 
Treatment for more than 
5 days 
Odds 
ratio 
3.0 
5.9 
3.5 
95% 
confidence 
interval p-value 
1 .I-&3 0.03 
2.1-16.7 0.002 
1.3-9.8 0.02 
of penicillin-resistant S. pneumoniae were exposure to 
p-lactams in the previous month, treatment with a lower 
dose than that recommended, and a longer duration of 
treatment (Table 3).32 
One approach is to reduce the duration of treat- 
ment, thus reducing the time for which the bacteria are 
exposed to antimicrobials, and to increase the dose, to 
more rapidly and completely reduce bacterial load. This 
approach was tested in a large randomized trial in 
children who required antimicrobial treatment for 
an RTI.33 One group of children received high-dose 
amoxicillin, 90 mgikg per day for 5 days, while the other 
received low-dose amoxicillin, 40 mg/kg per day for 
10 days. On day 28, nasopharyngeal carriage of penicillin- 
non-susceptible S. pneumoniae was detected in signifi- 
cantly fewer children who received a high dose for a 
shorter time than in those who received a low dose for 
a longer time (Table 4). The risk of cotrimoxazole 
resistance was also lower in the high-dose, short-course 
group. The finding that children in households of three 
or more children were at increased risk of penicillin- 
resistant S. pneumoniae carriage if they were treated 
with the low-dose, long course of amoxicillin suggests 
that this regimen would increase the likelihood of trans- 
mission of resistant organisms to other siblings. Not 
surprisingly, adherence to the shorter regimen was signi- 
ficantly better than adherence to the longer regimen 
(82% versus 74%;~=0.02).~~ 
The effect of high-dose amoxicillin-clavulanate 
(90 mg/kg per day b.i.d. for 10 days) on bacterial carriage 
was also studied in comparison with azithromycin 
(10 mglkg per day for 1 day, then 5 mglkg per day o.d. 
for 4 days) in children with acute otitis media.34 The 
carriage of both S. pneumoniae and Haemophilus 
influenzae was significantly reduced in the amoxicillin- 
clavulanate group by 2 weeks after therapy (p<O.OOl 
and p=O.O05, respectively; Figure 3), and this low rate 
of carriage was maintained for up to 2 months after 
initial treatment. In comparison, there was no significant 
change in carriage for either pathogen in the 
azithromycin group (Figure 3).34 Azithromycin eradi- 
cated 69% of azithromycin-susceptible strains and 
29% of azithromycin-resistant S. pneumoniae strains. 
Amoxicillin-clavulanate eradicated all of the penicillin- 
susceptible and -intermediate S. pneumoniae strains 
Table 4. Risk factors for nasopharyngeal carriage of penicillin- or cotrimoxazole-non-susceptible 5. pneumoniae in children 
receiving antimicrobials for RTls. Data from Schrag et al33 
Risk factor 
Short-course, Long-course, 
high-dose low-dose 
amoxicillin amoxicillin 
Relative risk 
(95% confidence 
interval) D-value 
Penicillin-non-susceptible 
5. pneumoniae carriage 
Cotrimoxazole-non-susceptible 
5. pneumoniae carriage 
Households with 23 children 
(penicillin-non-susceptible 
5. pneumoniae carriage) 
24% 32% 0.77 (0.60-0.97) 0.03 
17% 23% 0.77 (0.58-I .03) 0.08 
0.72 (0.52-0.98) 0.02 
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W Initial El+2 weeks 
Figure 4. Cost of inappropriate prescribing of antimicrobials 
for lower RTls. A match is defined as when the antimicrobial 
MIC for the pathogen is less than or equal to the susceptible 
breakpoint. Data from Boles et al.36 
(b) Carriage of H. influenzae 
High-dose 
amoxicillin-clavulanate 
Azithromycin 
1 
All All . 8L+ 
8 
4 
h PL- 
1 H Initial El+2 weeks / 
Figure 3. Comparison of the effects of high-dose amoxicillin- 
clavulanate (n=55) and azithromycin (n=60) on carriage of 
penicillin-susceptible (Pen-S), penicillin-intermediate (Pen-l) 
and penicillin-resistant (Pen-R) 5. pneumoniae and P-lactamase- 
positive (pL+) and -negative (PL-) H. influenzae.34 
and 73% of the penicillin-resistant strains from the 
nasopharynx.34 The effect of increasing the dose of 
amoxicillin can be demonstrated by comparison with a 
previous study in the same population using the 
conventional 45 mg/kg per day dose.35 In this study, the 
conventional formulation resulted in suppression of 
all penicillin-susceptible S. pneumoniae strains, 71% of 
intermediate strains, and 37% of resistant strains.35 
These studies demonstrate the importance of treating 
bacterial infection maximally at the first presentation, in 
order to eradicate the bacteria from the infection site 
and the nasopharynx, preventing the continued spread 
of resistant strains. 
BACTERIOLOGIC FAILURE INCREASES COSTS 
At best, failure to eradicate the causative organism 
in RTIs increases the risk that a second course of anti- 
microbial may be needed; in the worst scenario, the 
patient may require hospital admission and further anti- 
microbials, with the possibility of prolonged morbidity 
or even death. However, the costs of suboptimal 
antimicrobial therapy are not well understood. 
One recent study addressed the issue of the cost 
of inappropriate antimicrobial prescribing in a health 
management organization. 36 When the antimicrobial 
used to treat a lower RTI matched the in vitro suscepti- 
bility of the pathogen isolated, the costs were almost half 
of those accrued when an inappropriate agent was used 
(Figure 4).36 
The majority of RTIs are treated in the community, 
but the major cost of RTIs is due to the small proportion 
of patients who are hospitalized. For example, a recent 
Spanish study found that hospital admissions repre- 
sented 50-70% of the total costs of community-acquired 
pneumonia and 40-51% of the costs of acute exacer- 
bations of chronic bronchitis.37 In contrast, the cost 
of antimicrobial therapy represented only 2-13% and 
4-28% of total costs, respectively.37 Furthermore, the 
clinical effectiveness of the initial antimicrobial was the 
main parameter influencing the final total cost per 
patient cured.37 Similarly, a UK study found that the 
duration of hospitalization in patients admitted with 
acute exacerbations of chronic bronchitis was, on average, 
5.4 days shorter in patients who responded to first-line 
therapy.38 Thus, getting antimicrobial therapy ‘right first 
time’ by maximizing bacteriologic efficacy and therefore 
clinical outcomes is potentially cost-saving. As drug 
acquisition costs are minimal compared to the cost of 
treatment failure, the cost of initial therapy should not 
play a role in the choice of therapy. 
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CONCLUSIONS 
Bacterial eradication should be the goal of antimicrobial 
therapy. Bacterial eradication minimizes the risk of 
clinical failure, and therefore also minimizes the total 
cost of patient care. In addition, optimizing therapy will 
reduce the risk of the selection and spread of bacterial 
resistance. We should be assessing antimicrobials on 
their ability to eradicate bacterial pathogens, both 
in clinical practice and during drug development. 
Antimicrobials that fail to achieve bacteriologic 
eradication, including eradication of resistant strains of 
the key RTI pathogens, should no longer be used in the 
empirical treatment of RTIs. 
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